Allogene Therapeutics Inc
For the period ended Mar 31, 2025. Filed May 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 13, 2025
ALLO$0.93-12.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
(In thousands, except share amounts)
| Common Stock · Additional Paid-in Capital · Accumulated Deficit · Accumulated Other Comprehensive Income (Loss) · Total Stockholders’ Equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance - December 31, 2024 | 212,210,597 | $212 | $2,241,879 | $(1,819,823) | $(89) | $422,179 |
| Issuance of common stock upon exercise of stock options and vesting of RSUs | 2,158,522 | 2 | (2) | — | — | — |
| Issuance of common stock from ATM offering, net of commissions and offering costs of $0.2 million | 3,842,282 | 4 | 9,998 | — | — | 10,002 |
| Stock-based compensation | — | — | 12,175 | — | — | 12,175 |
| Employee stock purchase plan | 386,861 | 1 | 637 | — | — | 638 |
| Net loss | — | — | — | (59,733) | — | (59,733) |
| Net unrealized gain on available-for-sale investments | — | — | — | — | 132 | 132 |
| Balance - March 31, 2025 | 218,598,262 | $219 | $2,264,687 | $(1,879,556) | $43 | $385,393 |
| Common Stock · AdditionalPaid-inCapital · AccumulatedDeficit · AccumulatedOtherComprehensiveIncome (Loss) · TotalStockholders’Equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance - December 31, 2023 | 168,642,238 | $169 | $2,075,252 | $(1,562,233) | $(955) | $512,233 |
| Issuance of common stock upon exercise of stock options and vesting of RSUs | 1,551,729 | 1 | 793 | — | — | 794 |
| Vesting of early exercised common stock | — | — | 532 | — | — | 532 |
| Stock-based compensation | — | — | 11,924 | — | — | 11,924 |
| Employee stock purchase plan | 259,000 | — | 856 | — | — | 856 |
| Net loss | — | — | — | (65,000) | — | (65,000) |
| Net unrealized gain on available-for-sale investments | — | — | — | — | 28 | 28 |
| Balance - March 31, 2024 | 170,452,967 | $170 | $2,089,357 | $(1,627,233) | $(927) | $461,367 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.